2nd Annual Life Science Digital Transformation Conference

May 19-20, 2020 | Chicago, IL

DAY TWO | WEDNESDAY, MAY 20

8:30 REGISTRATION & COFFEE

9:00 CHAIRPERSON’S OPENING REMARKS

9:15 BREAKOUT DISCUSSION: EXCHANGE OF INNOVATIVE DIGITAL TRENDS AND CHALLENGES
During this interactive session, participants will engage in peer to peer discussion and dive into focused topics related to specific digital transformation innovations. Gathering with peers interested in similar inventive opportunities, each discussion group will provide invaluable insights into cutting-edge technologies and strategies applicable to digital efforts. All participants are given the opportunity to select a topic among those listed below to explore in a group led by an industry leader who will report key findings to the rest of the audience at the end of the session, maximizing all participants’ number of take-home messages.

GROUP 1: 3D printing pill doses
Shaheen Lakhan, THE LEARNING CORP

GROUP 2: AI for drug discovery
Nishtha Gupta, GLAXOSMITHKLINE

GROUP 3: Software as medical device
Girish Srinivasan, PHENOMX, INC.

9:45 PANEL – OUTSIDE INDUSTRY PERSPECTIVE: EXPLORING SUCCESSFUL DIGITAL INNOVATION MODELS

  • Opportunities and limitations of an all-digital model
  • Continuous improvement via consumer data analysis
  • Approaches to optimizing the user-experience
  • ROI achievements via the use of digital technology
  • Future projections of digital innovation efforts

MODERATOR:
Kimberly Gold, REED SMITH

PANELISTS:
Anna Kravets, ADIRA LLC
Ozge Kurtoglu, PEARSON
Cary Smithson, GRANT THORNTON LLP
Kiran Rane, SEARS HOME SERVICES

 

10:30 COFFEE & NETWORKING BREAK

 

11:00 BEST PRACTICES IN CALCULATING AND DEMONSTRATING RETURN ON DIGITAL INVESTMENTS
Accurately measuring outcomes of digitalization efforts to efficiently and thoroughly exhibit the value of innovative activities is integral to ensuring ongoing support and funding from corporate hierarchy. Efficiently showcasing the impact of transformation efforts across business operations presents many challenges as professionals must take into account not only concrete numbers demonstrating cost-effectiveness, but also more fluctuating factors influencing outcomes, such as team involvement and adherence to new business processes. Furthermore, defining timelines after which digital transformation effort results can accurately be calculated often diverge between corporate hierarchy and digital teams, adding to the complexity of providing a clear vision of results on investment.

PART ONE: EXPLORATION OF MEASUREMENT STRATEGIES FOR DIGITAL TRANSFORMATION INITIATIVES

  • Evaluation of immediate metrics vs. longer timelines
  • Assessment of human factors impact on ROI
  • Demonstrating positive outcomes of digital initiatives

Kris Cherukuri, Director, Enterprise Systems, SYSMEX AMERICA, INC.

11:30 PART TW0: BREAKOUT DISCUSSION: EXCHANGING ROI METRICS AND METHODS FOR DETERMINIG DIGITIZATION SUCCESS

  • Approaches for efficiently interpreting digital success
  • Identifying potential limits to transformation efforts
  • Practical metrics to evaluate and suggested timelines

Kris Cherukuri, Director, Enterprise Systems, SYSMEX AMERICA, INC.
Dustin Johnson, Global Customer Experience Portfolio IT Leader, AVANOS MEDICAL

12:00 LUNCHEON FOR ALL SPEAKERS, SPONSORS AND ATTENDEES

1:00 MAINTAINING COMPLIANCE WITH DATA PRIVACY RULES IN THE US AND EUROPE

  • Analysis of secure data collection methods
  • HIPAA and further US data protection rules
  • Ensuring compliance with the EU GDPR
  • Continued improvement in software analytics

Kimberly Gold, Partner, REED SMITH LLP

1:45 DIGITAL SCIENCE AND PHARMACEUTICAL R&D: OPPORTUNITIES AND PITFALLS

  • Defining digital sciences to provide greater clarity
  • Employing revolutionary digital science methodologies
  • Exploration of incremental and transformative opportunities
  • Mitigating challenges and pitfalls of digital science application

Ulo Palm, Senior Vice President Digital Sciences, ALLERGAN

2:15 COFFEE & NETWORKING BREAK

2:30 CLARIFYING WHEN DIGITAL TECHNOLOGY BECOMES SOFTWARE AS A MEDICAL DEVICE

  • FDA definition of software as a medical device
  • Regulatory implications of digital tech as a device
  • Avoiding the classification all while innovating

Richard Jackson, Software Engineering Manager, BIOLASE

3:15 COMMERCIALIZATION OF DIGITAL THERAPEUTICS DEFINING STEPS FOR DIGITAL THERAPEUTIC R&D

  • Differences & similarities of traditional treatments
  • Key regulatory strategies to commercial success
  • Discussion of quality & process management methods

Robert Dericotte, Co-founder, AMBLYOTECH

4:00 CLOSING REMARKS & CONFERENCE CONCLUSION

Share This